Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 261-530-8 | CAS number: 58976-65-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
GLDA-H4 was not irritating in an in vitro skin irritation test which was supported by the fact that GLDA-Na4 was not irritating to the rabbit skin.
GLDA-H4 was irritating in two in vitro tests (BCOP and ICE) and in an in vivo eye irritation test; GLDA-Na4 was not irritating to the eyes. The commercial product was also tested in vitro (ICE test) and showed only slight eye irritation.
No data are available to conclude about respiratory tract irritation.
Key value for chemical safety assessment
Skin irritation / corrosion
Link to relevant study records
- Endpoint:
- skin irritation: in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 17-Jun-2014 to 23-Jun-2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The study has been performed according to OECD and/or EC guidelines and according to GLP principles.
- Qualifier:
- according to guideline
- Guideline:
- other: EU method B.46 (In Vitro Skin Irritation: Reconstructed Human Epidermis Model Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Guideline no. 439: In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Amount / concentration applied:
- TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 10.3 to 10.4 mg moistened with 5 µl water
NEGATIVE CONTOL:
- Amount(s) applied (volume or weight with unit): 25 µl Phosphate buffered saline
POSITIVE CONTROL
- Amount(s) applied (volume or weight with unit): 25 µl
- Concentration (if solution): 5% (aq) Sodium dodecyl sulphate - Duration of treatment / exposure:
- Exposure: 15 minutes
Post incubation period: 42 hours - Details on study design:
- TEST SITE
- Area of exposure: human epidermis model
- % coverage: 0.38 cm2
REMOVAL OF TEST SUBSTANCE
- Washing (if done): phosphate buffered saline
- Time after start of exposure: 15 minutes
POST INCUBATION PERIOD
- 42 hours
SCORING SYSTEM:
- After a 42 hour incubation period, determination of the cytotoxic (irritancy) effect was performed. Cytotoxicity is expressed as the reduction of mitochondrial dehydrogenase activity measured by formazan production from MTT at the end of the treatment. Cell viability was calculated for each tissue as a percentage of the mean of the negative control tissues. - Irritation / corrosion parameter:
- other: other: percentage viability
- Value:
- 113
- Remarks on result:
- other:
- Remarks:
- Basis: other: percentage of control. Time point: 15 minutes. (migrated information)
- Interpretation of results:
- not irritating
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
It is concluded that this test is valid and that GLDA-H4 is non-irritant in the in vitro skin irritation test.- Executive summary:
Skin irritation is expressed as the remaining cell viability after exposure to the test substance. The relative mean tissue viability obtained after 15 minutes treatment with GLDA-H4 compared to the negative control tissues was 113%. Since the mean relative tissue viability for GLDA-H4 was above 50% after 15 minutes treatment GLDA-H4 is considered to be non-irritant.
The positive control had a mean cell viability of 35% after 15 minutes exposure. The absolute mean OD570(optical density at 570 nm) of the negative control tissues was within the laboratory historical control data range. The standard deviation value of the percentage viability of three tissues treated identically was less than 8%, indicating that the test system functioned properly.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not irritating)
Eye irritation
Link to relevant study records
- Endpoint:
- eye irritation: in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 18 August - 08 September 2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The study has been performed according to OECD and/or EC guidelines and according to GLP principles.
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 405 (Acute Eye Irritation / Corrosion)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.5 (Acute Toxicity: Eye Irritation / Corrosion)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.2400 (Acute Eye Irritation)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: Japanese Ministry of Agriculture, Forestry and Fisheries (JMAFF), 12 Nohsan, Notification No 8147, April 2011, including the most recent partial revisions.
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Species:
- rabbit
- Strain:
- New Zealand White
- Details on test animals or tissues and environmental conditions:
- - Source: Charles River France, L’Arbresle Cedex, France.
- Age at study initiation: Animalused within the study was 14 weeks old.
- Weight at study initiation: Body weights was 2991 grams.
- Housing: Individually housed in cages with perforated floors.
- Diet: Free access to pelleted diet for rabbits (Global Diet 2030 Harlan Teklad, Italy). Hay and wooden sticks were available during the study period.
- Water: Free access to tap water.
- Acclimation period: At least 5 days
Environmental controls for the animal room were set to maintain 18 to 24°C, a relative humidity of 40 to 70%, approximately 15 room air changes/hour, and a 12-hour light/12-hour dark cycle. Any variations to these conditions were maintained in the raw data and had no effect on the outcome of the study.
IN-LIFE DATES: From: 18 August - 08 September 2014 - Vehicle:
- unchanged (no vehicle)
- Controls:
- other: The other eye of the animal remained untreated and served as the reference control.
- Amount / concentration applied:
- TEST MATERIAL- Amount applied: 41.2 mg
- Duration of treatment / exposure:
- Single instillation on Day 1.
- Observation period (in vivo):
- The eyes of the animal were examined approximately 1, 24, 48 and 72 hours and 7, 14 and 21 days after instillation of the test substance.
- Number of animals or in vitro replicates:
- 1 male
- Details on study design:
- STUDY DESIGN
The study was performed in a stepwise manner and was started by treatment of a single rabbit (sentinel). Based on the results of the first animal the conclusion of the study was clear, therefore the two further rabbits assigned to the study were not treated.
PREEMPTIVE PAIN MANAGEMENT
One hour prior to instillation of the test substance, buprenorphine (Buprenodale®, Dechra Ltd., Stokeon-Trent, United Kingdom) 0.01 mg/kg was administered by subcutaneous injection in order to provide a therapeutic level of systemic analgesia. Five minutes prior to instillation of the test substance, two drops of the topical anesthetic alcaine 0.5% (SA Alcon-Couvreur NV, Puurs, Belgium) were applied to both eyes.
TREATMENT
The animal was treated by instillation of 41.2 mg of the test substance (a volume of approximately 0.1 mL), in the conjunctival sac of one of the eyes after gently pulling the lower lid away from the eyeball. The lids were then gently held together for about one second to prevent loss of the test substance. The other eye remained untreated and served as the reference control. One hour after treatment, the treated eye was not rinsed with water since no residual test substance was visible. Additional injections of buprenorphine 0.01 mg/kg were administered immediately after the 1-hour observation and at the end of the first day to reduce pain and distress. Immediately after the 24-hour observation, a solution of 2% fluorescein (Merck, Darmstadt, Germany) in water (adjusted to pH 7.0) was instilled into both eyes of each animal to quantitatively determine corneal epithelial damage. This procedure was repeated to assess recovery. Any bright green stained area, indicating epithelial damage, was estimated as a percentage of the total corneal area. Immediately after fluorescein examination on Day 2, in order to provide a continued level of systemic analgesia, buprenorphine 0.01 mg/kg and meloxicam (Metacam®, Boehringer Vetmed GmbH, Ingelheim/Rhein, Germany) 0.5 mg/kg were administered by subcutaneous injection. An additional injection of buprenorphine 0.03 mg/kg was supplied at the end of the day to reduce pain and distress. Additional injections of buprenorphine 0.03 mg/kg and meloxicam 0.5 mg/kg were administered again immediately after the 48-hour observation. After the final observation, the animal was sacrificed by intra-venous injection of Euthasol® 20% (AST Farma BV, Oudewater, The Netherlands).
REMOVAL OF TEST SUBSTANCE
-Washing: No
OBSERVATIONS
- Mortality/Viability: Twice daily.
- Toxicity: At least once daily.
- Body Weight: Day of treatment (prior to instillation) and after the final observation.
- Necropsy: No necropsy was performed according to protocol.
- Irritation: The eyes of the animal were examined approximately 1, 24, 48 and 72 hours and 7, 14 and 21 days after instillation of the test substance. The irritation scores and a description of all other (local) effects wererecorded.
SCORING SYSTEM:
The irritation was assessed according to the numerical scoring system according to OECD 405. - Irritation parameter:
- cornea opacity score
- Remarks:
- (opacity)
- Basis:
- mean
- Time point:
- other: 24, 48 and 72 hrs.
- Score:
- 2
- Max. score:
- 4
- Reversibility:
- fully reversible within: 21 Days
- Irritation parameter:
- iris score
- Basis:
- mean
- Time point:
- other: 24, 48 and 72 hrs.
- Score:
- 1
- Max. score:
- 2
- Reversibility:
- fully reversible within: 7 Days
- Irritation parameter:
- conjunctivae score
- Remarks:
- (redness)
- Basis:
- mean
- Time point:
- other: 24, 48 and 72 hrs.
- Score:
- 2.7
- Max. score:
- 3
- Reversibility:
- not fully reversible within: 21 Days
- Irritation parameter:
- chemosis score
- Basis:
- mean
- Time point:
- other: 24, 48 and 72 hrs.
- Score:
- 3.3
- Max. score:
- 4
- Reversibility:
- not fully reversible within: 21 Days
- Remarks on result:
- other: No chemosis was noted at 14 Days after instillation
- Irritant / corrosive response data:
- Irritation: Instillation of 41.2 mg of GLDA-H4 (a volume of approximately 0.1 mL) into an eye of one rabbit resulted in severe effects on the cornea, iris and conjunctivae. The corneal injury consisted of opacity and epithelial damage. As a result of the corneal injury, pannus (neovascularization of the cornea) was apparent at 7 and 14 days after instillation. The corneal injury resolved within 21 days. Iridial irritation was observed and resolved within 7 days. The irritation of the conjunctivae consisted of redness, chemosis and watery discharge. The effects were not fully recovered at termination (21 days after exposure). Reduced elasticity of the eyelids was noted from 48 hours after installation onwards and had resolved within 21 days after installation.
Corrosion: There was no evidence of ocular corrosion. - Other effects:
- Colouration/Remnants: No staining of (peri) ocular tissues by the test substance was observed and no test substance remnants were seen.
Toxicity/Mortality: No symptoms of systemic toxicity were observed in the animal during the test period and no mortality occurred. - Interpretation of results:
- Category 2A (irritating to eyes) based on GHS criteria
- Remarks:
- Migrated information: No interpretation of the data was done.
- Conclusions:
- Instillation of GLDA-H4 into a rabbit eye resulted in severe effects on the cornea, iris and conjunctivae. Effects on cornea and iris disappeared within the 21-day period; redness and chemosis were not fully recovered and watery discharge was still seen at termination (21 days after exposure). However, at 21 day the score was only slight (1 in a range of 0-3 or 0-4) and it was expected that these changes would also have disappeared in a few more days.
- Executive summary:
The study was carried out based on the guidelines described in:
OECD No.405 (2012) "Acute Eye Irritation / Corrosion"
EC, No 440/2008, B5: "Acute Toxicity: Eye Irritation/Corrosion"
EPA, OPPTS 870.2400 (1998): "Acute Eye Irritation"
JMAFF Guidelines (2000), including the most recent revisions.
A single sample of 41.2 mg of GLDA-H4 (a volume of approximately 0.1 mL) was instilled into an eye of one rabbit. Observations were made 1, 24, 48 and 72 hours and 7, 14 and 21 days after instillation.
Instillation of the test substance resulted in severe effects on the cornea, iris and conjunctivae. The corneal injury consisted of opacity and epithelial damage. As a result of the corneal injury, pannus (neovascularization of the cornea) was apparent at 7 and 14 days after instillation. The corneal injury resolved within 21 days. Iridial irritation was observed and resolved within 7 days. The irritation of the conjunctivae consisted of redness, chemosis and watery discharge. Reduced elasticity of the eyelids was noted 7 and 14 days after installation. Redness and chemosis were not fully recovered and watery discharge was still seen at termination (21 days after exposure). However, at 21 day the score was only slight (1 in a range of 0-3 or 0-4) and it was expected that these changes would also have disappeared in a few more days.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (irritating)
Respiratory irritation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In a standard tests for in vitro skin irritation, GLDA-H4 was not irritating which was supported by the fact that GLDA-Na4 was not irritating to the rabbit skin in vivo.
In a standard test for in in vitro eye irritation (BCOP) GLDA-H4 was irritating but no conclusion could be drawn and an in vivo study was performed in one rabbit. Effects on cornea and iris disappeared within the 21 -day period; redness and chemosis were not fully recovered and watery discharge was still seen at termination (21 days after exposure). However, at 21 day the score was only slight (1 in a range of 0-3 or 0-4) and it was expected that these changes would also have disappeared in a few more days. Finally, an in vitro ICE test was carried out with GLDA-H4 and with Dissolvine StimWell HTF (the commercial product). The ICE test was chosen as the results of the in vitro BCOP test with GLDA-H4 required an in vivo study, whereas a BCOP study followed by an in vivo study with Stimwell HTF would not be possible as a commercial product should not be tested in vivo. Secondly, the ICE test uses the complete eye (not only the cornea) and has additional parameters included such as histopathology. The results of the ICE test with GLDA-H4 again showed eye irritation requiring classification Cat. 2 whereas the ICE test with Stimwell HTF showed slight eye irritation but it would not need classification for this endpoint. The commercial product has a higher pH than GLDA-H4 (is less acidic).
In an acute inhalation toxicity test in which rats were exposed to the technically highest attainable concentration of GLDA-Na4, clinical signs of toxicity included slightly decreased breathing rate during exposure and sniffing in a few animals shortly after exposure up to 2 days after exposure. These signs only point at very slight respiratory irritation at a very high concentration.
Justification for selection of skin irritation / corrosion endpoint:
Well performed and reported study in vitro study supported by the results of an in vivo study with the read across substance GLDA-Na4.
Justification for selection of eye irritation endpoint:
Well performed and reported in vivo study (one animal) based on the results of an in vitro study (BCOP); supported by the results of two other in vitro studies (ICE), one with GLDA-H4 and one with the commercial product.
Effects on eye irritation: irritating
Justification for classification or non-classification
No classification is needed for skin irritation. GLDA-H4 induced eye irritation in vivo most probably due to its low pH as GLDA-Na4 was not irritating to the eyes. Although slight effects on the eyes were still seen in the tested animal 21 days after treatment, it was expected that these would have fully disappeared in a few more days. Therefore, because the score of corneal opacity was below 3 and the score for iritis was below 1.5, and because the effects observed are considered to be transient and were expected to have reversed in a few more days, and because GHS Cat. 2A is applicable when effects fully reverse within an observation period of normally 21 days (and no fixed period of 21 days), GLDA-H4 should be classified as an eye irritant Cat. 2A, which would be Cat. 2 in Europe. Another in vitro study with GLDA-H4 (ICE test) confirmed classification as eye irritant Cat. 2. The commercial product Dissolvine StimWell HTF did only induce slight eye irritation in the ICE test and would therefore not need classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.